- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07591662
Subthreshold Diode Laser Versus Trabeculotomy in Treatment of Advanced Primary Open Angle Glaucoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Glaucoma is a common eye disease that can cause irreversible blindness if left undiagnosed and untreated. Glaucoma is caused by elevated intraocular pressure (IOP) that leads to optic nerve damage and visual field loss.
Trabeculectomy operation was first described more than 50 years ago and is considered the most commonly performed surgery worldwide for glaucoma patients.
Subthreshold transscleral cyclophotocoagulation is a micropulse delivery mode of diode laser that has been used recently to treat glaucoma by ablating the ciliary processes and reducing the aqueous humour production.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kafrelsheikh
-
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
- Kafrelsheikh University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients older than 18 years.
- Open angle glaucoma.
- Advanced glaucoma (visual field deterioration MD>-12.00 dB with evidence of optic neuropathy despite maximal therapy).
Exclusion Criteria:
- Previous intraocular surgery for glaucoma.
- Patients who had undergone previous laser therapy for glaucoma.
- Cases of secondary glaucoma.
- Media opacity interferes with capturing fundus image.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A
Patients scheduled for subthreshold diode laser.
|
Patients scheduled for subthreshold diode laser.
|
|
Experimental: Group B
Patients scheduled for trabeculotomy.
|
Patients scheduled for trabeculotomy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual acuity
Time Frame: 12 months postoperatively
|
Visual acuity was evaluated using finger counting, hand motion, or light perception
|
12 months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraocular pressure
Time Frame: 12 months postoperatively
|
Intraocular pressure was measured and success criteria included an IOP ranging from 6 to 21 mmHg or a minimum 20% decline from baseline, with or without antiglaucoma drugs.
|
12 months postoperatively
|
|
Degree of pain
Time Frame: 12 months postoperatively
|
Postoperative pain was assessed using a visual analogue scale from 0 to 10 cm: 0-4 cm for mild, 5-7 cm for moderate, and 8-10 cm for intense pain.
|
12 months postoperatively
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD.22.12.724
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.